Volgende

Automatisch afspelen

Peptide Receptor Radionuclide Therapy (PRRT)

3 Bekeken • 07/09/23
Delen
insluiten
administrator
administrator
abonnees
0

One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).

NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.

What do physicians look forward to in the future for PRRT?

Laat meer zien
0 Comments sort Sorteer op
Facebook Reacties

Volgende

Automatisch afspelen